Trending
Stocks.org
You are at:»»AcelRx Pharmaceuticals Inc (NASDAQ:ACRX) Says FDA Asks for More Data on Zalviso
acelrx

AcelRx Pharmaceuticals Inc (NASDAQ:ACRX) Says FDA Asks for More Data on Zalviso

604
By on BioPharma

AcelRx Pharmaceuticals Inc (NASDAQ:ACRX), a biotech pharma focused on pain treatments, said the FDA issued a Complete Response Letter (CRL) for the Company’s new drug application (NDA) for Zalviso (sufentanil sublingual tablet system). The company is currently reviewing the FDA’s comments and requests contained in the CRL and plans to discuss these requests with the FDA.

The CRL contains requests for additional information on the Zalviso System to ensure proper use of the device. The requests include provision of bench data demonstrating a reduction in the incidence of optical system errors which require premature drug cartridge change, changes to the Instructions for Use for the device, and additional data to support the shelf life of the product.

The company said in a statement, “We believe some of the requests have been addressed in amendments to the NDA that have been submitted prior to the receipt of the CRL but, as acknowledged by the FDA, have not been reviewed. There is no guarantee that the information previously provided to the FDA will be adequate to address the issues in the CRL. Additional bench testing will be required and human factors testing may be required to address certain items in the CRL. There were no requests to conduct additional human clinical studies.”

“We believe we can satisfy all of FDA’s requests in the CRL and resubmit the NDA by the end of 2014, although we will have more clarity on the process and timing after our conversation with FDA,” said Richard King, president and CEO of AcelRx. “We are confident in the Zalviso development program and will work closely with the FDA to address the Agency’s concerns as outlined in the CRL to ensure that healthcare professionals and patient communities will have access to Zalviso.”

Get Free Updates and Stock Alerts!



*We only send one email per week
Share.

Related Posts

Get Winning Stock Alerts!

Our track record speaks for itself! Our last 7 alerts have delivered combined gains in excess of 300% and there are no signs of slowing down. Join UltimateStockAlerts.com now before you miss out on our next big runner!

We will never sell or share your information.
Close